Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Pediatric Hematology/Oncology and ImmunopathologyOpen Access

Post-transplant cyclophosphamide, abatacept, and vedolizumab for the prevention of graft-versus-host disease after hematopoietic stem cell transplantation in children with acute leukemia: results of a prospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

MPM. E. PerminovaDmitry Rogachev National Research Center of Pediatric Hematology, Oncology and ImmunologyЛШЛариса ШелиховаMKMaria KlimentovaDmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology

Discussion

Loading...

Member takes

Implication

Prospective study finds that enhanced GVHD prophylaxis lowers incidence in children with acute leukemia, suggesting improved outcomes.

Key Points

  • The cumulative risk of acute graft-versus-host disease (GVHD) grade II-IV was 38%, indicating effective prophylaxis in this setting.
  • After 2 years, the event-free survival rate was 85%, and overall survival reached 91% among children with high-risk acute leukemia.
  • A prospective study evaluated a regimen combining post-transplant cyclophosphamide, vedolizumab, and abatacept for safety and efficacy.
  • The results demonstrate a beneficial safety profile with no specific adverse events reported, highlighting the regimen's tolerability.

Cite This Study

Perminova et al. (2025) studied this question.

synapsesocial.com/papers/68c23cf6b210217d6478bb81https://doi.org/10.24287/1726-1708-2025-24-2-38-45
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Experience with post-transplant cyclophosphamide (PTCy) for GVHD prophylaxis in HLA-matched related donor HSCT in pediatric and adult patients. evidence of real-life outcomes from a Latin American transplant center.2025
  2. 2Combination of post-transplant cyclophosphamide and anti-thymocyte globulin for haploidentical stem cell transplantation in pediatric patients with acute leukemia2026
  3. 3Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  4. 4Post‐Transplant Cyclophosphamide for Graft‐Versus‐Host Disease Prophylaxis in Pediatric Stem Cell Transplantation2025
  5. 5Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation2025 · 1 citations